key: cord-0885985-xdq3m350
authors: Olsson-Brown, A. C.; Hughes, D. J.; Purshouse, K.; Lee, L.; Cheng, V. W.; Lee, A.J.X.; Protheroe, E.; Smith, A.; Curley, H.; Arnold, R.; Cazier, J-B.; D'Costa, J.; Palles, C.; Campton, N.; Varnai, C.; Sivakumar, S.; Kerr, R.; Middleton, G.
title: UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic
date: 2020-09-30
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2020.08.1767
sha: 80584c6483535700f219eecb393a3fd2d0c967df
doc_id: 885985
cord_uid: xdq3m350

nan

Methods: The ability to set up an interdisciplinary multi-organisational team quickly, covering expert knowledge from clinical, legal, statistical, and computer science was essential. The technical infra-structure allows clinician-led anonymised data entry and rapid dissemination of results with a clinical (RedCap) database as core. However the development of a national cancer reporting network was crucial for the viability of the project. From its inception in March 2020 the reporting network was established via 4 iterative phases.

Results: Within the first 4 weeks, >50 centres were involved with coverage throughout the UK. Expansion has continued with >70 centres within 6 weeks reporting over 1200 COVID positive cancer patients. This was achieved through a 4-phase approach: phase 1 -Outline: This involved project protocol development where key data and timelines were confirmed by a small project team followed by whole-team sign-off. phase 2 -Engagement: This involved identification and engagement of existing groups to establish an initial network. Professional body endorsement led to increased recognition and utilisation of their membership networks. Finally regional leads were identified. phase 3 -Invitation: The third phase involved the distribution of a formal invite letter via identified networks. Project specific email and standard mailing lists were created to enhance network identity and communication. phase 4 -Consolidation: Early development of an interactive project website and focus on communication via social media with varied content consolidated interest and led to further extension.

Conclusions: Real-time reporting of real world data can be achieved with clearly defined project phases, standardised documentation and an iterative recruitment process. The COVID-19 pandemic necessitated a rapid response, proving that similar reporting networks can be set up quickly and robustly to react to the evidence-based needs of the oncology community in the drive for implementation of change.

Legal entity responsible for the study: The authors. Background: The COVID-19 (C19) pandemic has prompted alterations to systemic anti-cancer therapy (SACT) due to concerns of immunosuppression and healthcare exposure. However, the effects of SACT on mortality in patients who acquire C19 are not well understood. As a national cancer centre within a major C19 hotspot, we seek to address these risks at scale.

Patients with a history of solid cancers and laboratory confirmed C19 (1 Mar to 31 May 2020) were included. Haematological malignancies were excluded. The primary outcome was time from C19 diagnosis to death. The last follow-up date was 22 Jun 2020.

We identified 94 cancer patients; 62 males (median age 73, BMI 24.9), and 32 females (median age 68.5, BMI 25.7). Genitourinary (n ¼ 24) cancers were the most common, followed by gastrointestinal (n ¼ 23), thoracic (n ¼ 15), and gynaecological (n ¼ 9) cancers. 25 patients received SACT: chemotherapy (n ¼ 15), endocrine therapy (n ¼ 8), immunotherapy (n ¼ 4), and targeted anti-cancer therapy (n ¼ 2). 16 patients received SACT with palliative intent. Patients on SACT had a greater incidence of metastatic disease (48.0% vs 10.6%, p <0.001) and were younger (median age 62.5 vs 73.0, p ¼ 0.01). They were also more likely to have renal impairment (p ¼ 0.02), lymphopaenia (p ¼ 0.01) and anaemia (p ¼ 0.04) compared to those not on SACT. The univariate analysis showed age and co-morbidities were associated with mortality (Table) . Adjusting for age, ethnicity, co-morbidities and the presence of metastatic cancer, SACT was an independent risk factor for C19 mortality (HR 2.46, 1.09 e 5.5, p ¼ 0.03). Age, South Asian ethnicity, hypertension and cerebrovascular disease were also independent risk factors for C19 mortality.

Conclusions: C19 infection poses a substantial risk to cancer patients and our data suggests that SACT is an independent risk factor for mortality in C19 infection. These findings call for a nuanced approach to C19 risk, focusing on established risk factors such as age and co-morbidities to guide treatment decisions.

Legal entity responsible for the study: University College London Hospital.

Funding: Has not received any funding. 

Medical Oncology Department, IOV -Istituto Oncologico Veneto IRCCS

Senatore Antonio Perrino Hospital

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Background: Cancer patients are more susceptible to infections and potentially at higher risk to develop COVID-19

Methods: To analyze the distribution of patients who developed COVID-19 during active antineoplastic therapy and the related clinical course by tumor type, stage and class of oncologic treatment (chemo, immune, biologic, other) a multicenter, retroprospective, observational study was proposed to the Hospital Medical Oncologic Units of the National Health Service in Italy (168 centers of the Collegio Italiano dei Primari Oncologi Medici Ospedalieri -CIPOMO). Data were collected on demographics, tumor characteristics, treatment setting, type of ongoing anti-cancer therapy and COVID-19 clinical course (phenotype, hospitalization, therapy, duration and outcome)